Armed Cell Therapeutics, chaired by former Galapagos CEO Paul Stoffels, has assumed control of cell therapies after the company—now known as Lakefront Biotherapeutics—divested in a strategic overhaul. The move effectively re-energizes Galapagos’ CAR-T research footprint under a new corporate umbrella. The repositioning highlights how strategic exits and reorganizations can be followed by a resurgence of therapeutic-area focus, especially in cell therapy where timelines and manufacturing constraints require sustained platform capability. For the market, the news signals renewed attention to CAR-T execution and pipeline continuity through ownership transitions. The key question for investors will be how quickly Lakefront can translate inherited assets into trial-readiness while aligning manufacturing and clinical development plans to current industry standards.